ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston, MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he explained to Peter Goodwin, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310AyalAizerAJOPODCASTLoRes.mp3]
